Abbott Laboratories (ABT)
-NYSE 37.72 0.00(0.00%) May 22, 4:04PM EDT|After Hours
:
37.72 0.00 (0.00%) May 22, 5:40PM EDT
| Prev Close: | 37.72 |
|---|
| Open: | 37.71 |
|---|
| Bid: | 37.62 x 100 |
|---|
| Ask: | 38.75 x 300 |
|---|
| 1y Target Est: | 39.94 |
|---|
| Beta: | 0.53 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 37.60 - 38.77 |
|---|
| 52wk Range: | 28.46 - 38.77 |
|---|
| Volume: | 9,983,014 |
|---|
| Avg Vol (3m): | 7,361,750 |
|---|
| Market Cap: | 58.80B |
|---|
| P/E (ttm): | 11.50 |
|---|
| EPS (ttm): | 3.28 |
|---|
| Div & Yield: | 0.56 (1.50%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Featured on Yahoo! Finance
Headlines
- CE Mark for Abbott's Xience Xpedition 48Zacks(Wed, May 22)
- A Moderate-Risk, High-Reward Dividend Playat Seeking Alpha(Wed, May 22)
- Abbott to Present at Deutsche Bank 38th Annual Health Care ConferencePR Newswire(Wed, May 22)
- AbbVie Reaches New Highs Thanks To Humiraat Seeking Alpha(Wed, May 22)
- AbbVie: Sliding Safely Instead Of Falling Off The Patent Cliffat Seeking Alpha(Wed, May 22)
- For U.S. Companies, Money ‘Offshore’ Means Manhattanat New York Times(Tue, May 21)
- InPlay: Abbott Labs announces CE Mark for world's longest coronary drug eluting stentBriefing.com(Tue, May 21)
- Abbott Announces CE Mark for World's Longest Coronary Drug Eluting StentPR Newswire(Tue, May 21)
- Coverage initiated on Abbott Labs by Gabelli & CoBriefing.com(Tue, May 21)
- Johnson & Johnson Stock Checkup for Mayat Motley Fool(Tue, May 21)
- Analyst Moves: ABT, ACN, EFX, JCPat Forbes(Mon, May 20)
- Why This Stock Could Be a Smart Investmentat Motley Fool(Mon, May 20)
- Analysts: Boeing’s Outlook Is Positive and 3 More Research Notes to Exploreat Wall St. Cheat Sheet(Mon, May 20)
- July Options Now Available For Abbott Laboratories (ABT)at Forbes(Mon, May 20)
- 5 Drugs Stocks On The Riseat TheStreet(Mon, May 20)
Key Statistics
| Forward P/E (1 yr): | 16.76 |
|---|
| P/S (ttm): | 1.47 |
|---|
| Ex-Dividend Date: | 11-Apr-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 2.01 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.44 |
|---|
| Mean Recommendation*: | 2.6 |
|---|
| PEG Ratio (5 yr expected): | 1.52 |
|---|
Business Summary
Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine ins...
View More 
0.52%